Phase 3 data found the Moderna RSV vaccine was 83.7% effective against RSV-associated lower respiratory tract disease in adults age 60 and older. The FDA has granted the vaccine a Breakthrough Therapy Designation.
A 50 µg dose of Moderna's bivalent booster candidate, mRNA-1273.214, demonstrated superior neutralizing antibody response against the Omicron variant one month after administration when compared to the original mRNA-1273 vaccine.
The FDA expanded emergency use for both the Moderna and Pfizer-BioNTech COVID-19 vaccine boosters for all individuals 18 years of age and older.
The FDA has requested that vaccine companies expand their trials in several thousand children before seeking emergency authorization.
Read More
The FDA has reported increased risks of myocarditis and pericarditis following vaccination with the Moderna and Pfizer-BioNTech COVID-19 vaccine.
Read More
The Biden Administration will ship 2 million doses of the Pfizer/BioNTech COVID-19 vaccine to Peru and 2.5 million doses of the Moderna vaccine to Pakistan.
Read More
The US government has purchased an additional 200 million doses of Moderna’s COVID-19 vaccine, including the option to purchase other COVID-19 vaccine candidates from Moderna’s pipeline.
Read More
Moderna Inc has requested an emergency use authorization for its COVID-19 vaccine in adolescents age 12 to 17 with the FDA. The vaccine has been authorized for adults age 18 and older since December 2020.
Read More
A new CDC study reports the mRNA COVID-19 vaccines from Pfizer-BioNTech and Moderna reduce the risk of infection by 91% for fully vaccinated people.
Read More
A Phase 2/3 study of the Moderna COVID-19 vaccine (mRNA-1273) in adolescents age 12-17 was 93% effective and well tolerated, according to the company.
Read More
Some young people who received COVID-19 vaccines experienced heart inflammation, according to a statement from the US Centers for Disease Control and Prevention.
Read More
A CDC study of 1,843 healthcare workers found that COVID-19 mRNA vaccines from Pfizer-BioNTech and Moderna reduced the risk of infection by 94% among HCWs who were fully vaccinated.
Read More
Immunological memory, the very thing that offers continued protection against a virus long after vaccination, may negatively interfere with vaccine booster shots.
Read More
The CDC reports risk of COVID-19 infection following the second dose of Moderna or Pfizer’s vaccine was reduced by 90% two or more weeks after vaccination.
Read More
The Cystic Fibrosis Foundation issued a statement encouraging people with cystic fibrosis to talk with their CF care team about getting vaccinated.
Read More